ADALTA LIMITED — AGM Information 2022

Sep 26, 2022

==> picture [186 x 44] intentionally omitted <==

27 September 2022

ASX Announcement

NOTIFICATION OF DATE OF 2022 ANNUAL GENERAL MEETING

MELBOURNE Australia, 27 September 2022: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform advises that the Company’s Annual General Meeting (AGM) will be held as a hybrid meeting on 22 November 2022 at 11:00am AEDT at K&L Gates, Level 25, Rialto South Tower, Melbourne VIC 3000 and via Zoom.

Further to Listing Rules 3.13.1 and 14.3 and the Company Constitution, nominations for election of directors at the AGM must be received not less than 35 Business Days before the meeting, being no later than 4 October 2022.

Following formalities, AdAlta’s CEO and Managing Director, Dr Tim Oldham will provide an update to shareholders.

In order to receive electronic communications, shareholders are encouraged to contact the share registry, Automic Group, via the details below:

• Visit: www.automicgroup.com.au

• Email: hello@automic.com.au

• Telephone: (Within Australia) 1300 288 664 (Outside Australia) +61 2 9698 5414

Authorised for lodgement by:

Tim Oldham

CEO and Managing Director September 2022

==> picture [519 x 38] intentionally omitted <==

==> picture [186 x 44] intentionally omitted <==

Notes to Editors

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today’s most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immunooncology drugs, a program now in pre-clinical development.

AdAlta’s strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: https://adalta.com.au

For more information, please contact:

Investors

Media

Tim Oldham, CEO & Managing Director IR Department Tel: +61 403 446 665 Tel: +61 411 117 774 E: t.oldham@adalta.com.au E: jane.lowe@irdepartment.com.au

==> picture [519 x 38] intentionally omitted <==